Courses a.y. 2021/2022
10911 ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES
11383 VALUTAZIONE ECONOMICA IN SANITA' [ECONOMIC EVALUATION IN THE HEALTHCARE SECTOR]
11396 POLITICHE E SISTEMI DI GESTIONE DEI DISPOSITIVI MEDICI [POLICIES AND MANAGEMENT SYSTEMS OF MEDICAL DEVICES]
11449 PRINCIPI DI PROCESS E PROJECT MANAGEMENT NELLE AZIENDE SANITARIE E SOCIO-ASSISTENZIALI [BASICS OF PROCESS AND PROJECT MANAGEMENT IN HEALTHCARE SECTOR AND SOCIAL SERVICES]
11938 PUBLIC VALUE & PERFORMANCE MANAGEMENT
20574 REGULATION AND ECONOMICS OF HEALTHCARE INDUSTRY
30009 ECONOMIA E MANAGEMENT DELLE AMMINISTRAZIONI PUBBLICHE [PUBLIC ADMINISTRATION ECONOMICS AND MANAGEMENT]
30444 PUBLIC MANAGEMENT (BUSINESS GOVERNMENT RELATIONS)
Università Bocconi 1992, degree in Business Administration. MSc in Health Services Management with distinction at the University of London in 1996. PhD in Public Health and Policy at the University of London in 2003.
Associate Dean, Divisione Government, Health and Nonprofit, SDA Bocconi School of Management, Università Bocconi. Associate Professor in Healthcare Management at the Department of Social and Political Science.
Economic evaluation analysis of healthcare programmes, health policy, healthcare management, health technology assessment and budget impact analysis.
Tarricone R, Ciani O, D’Acunto S, Scalzo S. The rise of rules: Will the new EU regulation of medical devices make us safer? EJIM https://doi.org/10.1016/j.ejim.2020.07.012
Tarricone R, Rognoni C, Arnoldo L, Mazzacane S, Caselli E. A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis. Pathogens 2020, 9, 502.
Rognoni C, Lugli M, Maleti O, Tarricone R. Venous stenting for patients with outflow obstruction and leg ulcers: cost-effectiveness and budget impact analyses. Journal of Comparative Effectiveness Research, 0.2217/cer-2020-0030
Rognoni C, Tozzi M, Tarricone R. Endovascular versus surgical creation of arteriovenous fistula in hemodialysis patients: cost-effectiveness and budget impact analyses. Journal of Vascular Access 2020; doi: 10.1177/1129729820921021
Drummond M, Torbica A, Tarricone R. Should health technology assessment be more patient centric? If so, how? The European Journal of Health Economics 2020; doi: 10.1007/s10198-020-01182-z
Torbica A, Fornaro G, Tarricone R, Drummond M. Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis. Value in Health 2020;23(1):17-24.
Boscolo PR, Callea G, Ciani O, Tarricone R. Measuring Value in Health Care: A Comparative Analysis of Value-based Frameworks. Clinical Therapeutics 2020;42(1):34-43.
Tarricone R, Cucciniello M, Armeni P, Petracca P, Desouza K, Hall LK, Keefe D. Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results from a Cross-Sectional International Survey. JMIR mHealth and uHealth 2019;7(9); doi: 10.2196/13584.
Torbica A, Tarricone R, Drummond M. Does the approach to economic evaluation in health care depend on culture, values and institutional context? The European Journal of Health Economics 2018;19(6):769-774
Tarricone R, Torbica A, Drummond M. Challenges in the Assessment of Medical Devices: the MedtecHTA project. Health Economics 2017;26(Suppl S1):5-12.
Tarricone R, Torbica A, Drummond M. (for the MedtecHTA project group) Key Recommendations from the MedtecHTA Project. Health Economics 2017;26(Suppl S1):145-152.
Tarricone R, Callea G, Ogorevc M, Prevolnik Rupel V. Improving the methods for the economic evaluation of medical devices. Health Economics 2017;26(Suppl S1):70-92
Callea A, Armeni P, Marsilio M, Jommi C, Tarricone R. The impact of HTA and procurement practices on the selection and prices of medical devices. Social Science and Medicine 2017; 174:89-95.
Drummond M, Tarricone R, Torbica A, “Incentivising research into the effectiveness of medical devices” European Journal of Health Economics 2016; 17:1055-1058.
Tarricone R, Boscolo P.R, Armeni P. What type of clinical evidence is needed to assess health technologies? European Respiratory Review, 2016;25:259-265
Armeni P, Boscolo PR, Tarricone R, Capodanno D, Maggioni A, Grasso C, Maisano F. Real-World Cost Effectiveness of Mitraclip combined with Medical Therapy Versus Medical Therapy Alone in Patients With Moderate or Severe Mitral Regurgitation. International Journal of Cardiology 2016; 209:153-160.
Rognoni C, Meregaglia M, Tarricone R, Efficacy and safety of iron supplementation in anaemic patients: a systematic review and meta-analysis of randomized controlled trials. Clinical Drug Investigations 2016; 36(3):177-194
Tarricone R, Medina Lara A, Abu Koush D. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. Critical Reviews in Oncology/Hematology 2016; 99:37-48.
Tarricone R, Ricca G, Nyanzi-Wakholi B, Medina Lara A. Impact of cancer anorexia-Cachexia Syndrome on Health-Related Quality of Life and Resource Utilisation: a Systematic Review. Critical Reviews in Oncology/Hematology 2016; 99:49-62.
Sommariva S, Pongiglione B, Tarricone R. Impact of Chemotherapy- Induced Nausea and Vomiting on Health-Related Quality of Life and Resource Utilization: a Systematic Review. Critical Reviews in Oncology/Hematology 2016; 99: 13-36.
Valzania C, Torbica A, Tarricone R, Leyva F, Boriani G. Implant rates of cardiac implantable electrical devices in Europe: a systematic literature review. Health Policy 2016;120(1):1-15
Generali D, Venturini S, Rognoni C, Ciani R, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment 2015;152(1):95-117.
Gonzales FM, Finch AP, Armeni P, Boscolo PR, Tarricone R. Comparative Effectiveness of Mitraclip versus Optimal Medical Therapy in High-Risk Surgical Patients: a Comprehensive Review. Expert Review of Medical Devices 2015;12(4): 471-485.
Beresniak A, Medina-Lara A, Auraye JP, Weverf A, Praetf JC, Tarricone R, Torbica A, Dupont D, Lamure M, Durue G. Validation of the underlining assumptions of the QALY outcome: results from the ECHOUTCOME European project. Pharmacoeconomics 2015;33(1):61-69.
Gehring M, Jommi C, Tarricone R, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiology, Biostatistics and Public Health 2015;12(1):1-9.
Tarricone R, Torbica A, Ferrè F, Drummond M. Generating Appropriate Clinical Data for Value Assessment of Medical Devices: What Role Does Regulation Play? Expert Review of Pharmacoeconomics and Outcome Research 2014;14(5):707-718.
A. Compagni, A. Melegaro, R. Tarricone. Genetic Screening for the Predisposition to Venous Thromboembolism: A Cost-Utility Analysis of Clinical Practice in the Italian HealthCare System. Value in Health 2013; 16: 909-921.
O Ciani, D Grassi, R Tarricone. An economic perspective on urinary tract infection: the "costs of resignation". Clinical Drug Investigation 2013; 33(4): 255-261
S. Calciolari, A. Torbica, R. Tarricone. Explaining the health costs associated with managing intracranial aneurysms in Italy. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2013; 11(4): 427-435.
BD Smith, R. Tarricone, V. Vella. The role of product life cycle in medical technology innovation. Journal of medical marketing 2013; 13(1): 37-43.
G Callea, R. Tarricone, R Mujica Mota. The economic impact of a medical device company’s location in Italy. Journal of medical marketing 2013; 13(1): 24-36.
R. Tarricone. Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. Value in Health 2013; 16(1 suppl):S4-S6
M. Drummond, R. Tarricone, A. Torbica. Assessing the added value of health technologies: reconciling different perspectives. Value in Health 2013; 16(1 suppl): S7-S13.
R. Tarricone, A. Torbica. Costing and performance in healthcare management. Faltin, F.W, Kenett, R.S., Ruggeri, F. (a cura di) Statistical methods in healthcare. Wiley, UK, 2012, pp.386-404.
G. Callea, R. Tarricone, A. Medina Lara. Economic evidence of interventions for acute myocardial infarction: a review of the literature. EUROINTERVENTION 2012;8:P71-P76.
R. Mujica-Mota, R. Tarricone, O. Ciani, J.F.P. Bridges, M. Drummond. Determinants of demand for total hip and and knee arthroplasty: a systematic literature review. BMC Health Services Research 2012;12:225-257.
O. Ciani, R. Tarricone, A. Torbica. Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? Health Policy 2012; 108(2-3):194-202.
R. Tarricone (a cura di). Politiche per la salute e scelte aziendali. Impatto sull’innovazione e diffusione delle tecnologie mediche. EGEA, 2012.
A. Compagni, A. Melegaro, R. Tarricone. Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism. Italian Journal of Public Health 2012;9:s36-s45.
C Sorenson, R Tarricone, M Siebert, M Drummond. Applying Health Economics for Policy Decision Making: Do Devices Differ From Drugs?. EUROPACE 2011;13:ii54-ii58.
R. Tarricone. Innovazione e competitività dei sistemi industriali regolati. le imprese dei dispositivi medici. EGEA, 2010.
R. Tarricone, A. Torbica, F. Franzetti, V.D. Rosenthal. Hospital cost of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Effectiveness and Resource Allocation 2012;8:1-10.
Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. UROLOGY 2010;75:491-500.
M. Drummond, A. Griffin, R. Tarricone. Economic evaluation for devices and drugs. Same or different? Value in Health 2009; 12(4):402-404.
R. Tarricone, A. Tsouros. Homecare in Europe. The solid facts. WHO, 2008
G. Fattore, MC Cavallo, R. Tarricone. Lo sviluppo dell’Health Technology in Italia: contenuti, approcci e riferimenti internazionali. In Rapporto OASI 2008. L’aziendalizzazione della sanità in Italia. EGEA, 2008.
R. Tarricone, G. Aguzzi, F. Musì, L. Fariselli, A. Casasco. Cost-effectiveness for trigeminal neuralgia: Cyberknife vs microvascular decompression. Neuropsychiatric Disease and Treatment 2008; 4(3):647-652.
P. Roggero, R. Tarricone, V. Mangiaterra, et al. What do people think about disabled youth and employment in developing and developed countries? Results from an e-discussion hosted by the World Bank. Disability and Society 2006;21(6):645-650
R. Tarricone. COI analysis: what room in health economics? Health Policy 2006;77(1):51-63
R. Tarricone, F. Girolami. Economic evaluation of a new antiemetic drug: palonosetron vs ondansetron. Clinical Drug Investigation 2005; 25(9):597-608.
S. Gerzeli, R. Tarricone, P. Zolo, et al. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. Neurological Science 2005; 26(2):72-80.
R. Tarricone, Valutazioni economiche e management in sanità. Applicazioni ai programmi e tecnologie sanitarie, Milano, McGraw-Hill, 2004.
R. Tarricone, E. Martelli, F. Parazzini, J. Darbà, C. Le Pen, J. Rovira, "Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain". Clinical Drug Investigation 2001;21(7): 453-464
G. Fattore, S. Gerzeli, R. Tarricone, "The costs of farmacological treatment for major depression. The Italian prospective multi-centre observational incidence-based study", Pharmacoeconomics, 2000, n. 2: 167-174
R. Tarricone, S. Gerzeli, R. Montanelli, L. Frattura, M. Percudani, G. Racagni Direct and indirect costs of Schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 2000; 51:1-18